Furthermore, HIF-1α has been suggested as a potential therapeutic target using small interference (si)RNA, packaged in a novel surfactant-based nucleic acid carrier and delivered into gliomas of an In vivo orthotopic mouse model by osmotic pumps [149]. This evidence concerns the gene HIF1A and central nervous system cancer.